Loading clinical trials...
Loading clinical trials...
A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant
Conditions
Interventions
Pumarix™
Pandemrix ™
Locations
10
United States
GSK Investigational Site
Huntsville, Alabama, United States
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Stockbridge, Georgia, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Missoula, Montana, United States
Start Date
July 28, 2007
Primary Completion Date
June 17, 2008
Completion Date
October 24, 2008
Last Updated
August 17, 2018
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions